The development of therapeutic agents that modulate the immune system (IS) to induce or potentiate its anti-tumour activity has revolutionized cancer treatment in recent years. Focusing on the IS of the host rather than the tumour has proven to be an effective strategy in a number of tumours. However, this approach is not new. In the late 19th century, William Coley noticed that some patients affected by sarcoma had tumour response when injected locally with bacteria-derived toxins in what seemed to be an immune-driven effect [1].
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kCa57I
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Many different quantitative techniques have been developed to either assess Environmental Justice (EJ) issues or estimate exposure and dose ...
-
Leddsmerter kan ha mange årsaker. Traumatiske, immunologiske og infeksiøse lidelser må vurderes. En god anamnese kan sette oss på rett spor...
-
Trends in Otolaryngology Consultation Patterns at an Academic Quaternary Care Center. JAMA Otolaryngol Head Neck Surg. 2017 Jan 05;: ...
-
Abstract An intriguing piece of evidence for the inflammatory story of type 2 diabetes has come to the light. A recent study by Okin and co...
-
Variable Speed Limit Sign (VSLS) Systems enable speed limits to be changed dynamically in response to traffic conditions so that traffic inc...
-
Outcomes of Drug-Induced Sleep Endoscopy-Directed Surgery for Pediatric Obstructive Sleep Apnea. Otolaryngol Head Neck Surg. 2017 Nov ...
-
The promise of omics-based approaches to cancer prevention. Semin Oncol. 2016 Feb;43(1):36-48 Authors: Meerzaman D, Dunn BK, Lee M, C...
-
Prof Stupp speaks with ecancer at AACR 2017 about developing treatments for glioblastoma, from temozolomide and chemotherapy to novel tumour...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου